PreludeDx Appoints Chris Emery, VP of Strategic Marketing and Business Development
LAGUNA HILLS, Calif., Feb. 8, 2024 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced the appointment of Chris Emery to the newly created position of VP of Strategic Marketing and Business Development.
- LAGUNA HILLS, Calif., Feb. 8, 2024 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced the appointment of Chris Emery to the newly created position of VP of Strategic Marketing and Business Development.
- "With his extensive experience in healthcare and specifically molecular diagnostics, I am pleased to welcome Chris to PreludeDx's leadership team.
- Chris brings more than 25 years of experience in healthcare across laboratory services, medical device and biopharmaceutical companies, with senior leadership roles in marketing, sales and business development in the cancer diagnostics market.
- He joins PreludeDx from HALO Precision Diagnostics where he served as the Chief Business Officer – Molecular Diagnostics.